



August 31, 2018

Pharmacy Announcement

## Pharmacy and Therapeutics (P&T) Committee Makes Changes to Preferred Drug List (PDL) Effective September 1, 2018

On June 28, 2018, the Pharmacy and Therapeutics (P&T) committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective September 1, 2018. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Analgesics: Opiate Agonists - Abuse Deterrent	Morphabond®	Arymo® ER
Cardiovascular Agents: Antihypertensive Agents - Direct Renin Inhibitors	Class removed from the PDL	
Gastrointestinal Agents: Antiemetics - Miscellaneous		Bonjesta®
Hormones and Hormone Modifiers: Antidiabetic Agents - Incretin Mimetics	Ozempic®	
Hormones and Hormone Modifiers: Antidiabetic Agents - Insulins (Vials, Pens and Inhaled)		Admelog® Fiasp®
Hormones and Hormone Modifiers: Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors		Qtern® Segluromet® Steglatro® Steglujan™
Monoclonal Antibodies for the Treatment of Respiratory Conditions <i>(New)</i>	Nucala® Xolair®	Cinqair® Fasenra®
Ophthalmic Agents: Antiglaucoma Agents	Rhopressa®	Bimatoprost® Vyzulta®
Respiratory Agents: Respiratory Anti-inflammatory Agents - Respiratory Corticosteroids		Qvar® Redihaler™
Respiratory Agents: Respiratory Anti-inflammatory Agents - Nasal Corticosteroids	Triamcinolone Acetonide	Nasonex® Xhance™
Respiratory Agents: Respiratory Antimuscarinics		Trelegy Ellipta®